News

The new facility is the company’s second plasma center in Jacksonville and has now officially opened for business. The plasma donated at Biotest Plasma Centers is used to

AURION is designed to examine biomarkers of disease activity at eight weeks and their ability to predict response at 24 and 48 weeks. Patient enrolment in this small

The trial’s safety segment is designed to evaluate two doses (60mg/m2 and 90mg/m2) of Liposomal Grb-2 in combination with Ara-C front line therapy, while each dose group will

Around 1,800 patients will be enrolled from across 180 study centres globally in this randomized, double-blind, double-dummy, parallel group multicentre Phase III FULFIL trial. The trial is designed

Adocia’s HinsBet formulation incorporates BioChaperone technology which allows accelerated absorption of prandial insulins. The company said that the trial met its primary endpoint, measuring the increase of recombinant

Acelex has a new mode of action that specifically targets affected joints to relieve pain and restore mobility, while simultaneously preserving the integrity and safety of the gastrointestinal

The patent protects the improved modular design of EnWave’s nutraREV machinery, which is the most commercially advanced platform in the Company’s technology portfolio. EnWave has sold or received

Currently, the company is applying its Lecinoxoid technology to anti-inflammatory indications, including psoriasis and ulcerative colitis. The latest patent provides intellectual property rights in validated European countries through

Based on the results of this study (DRM04-HH02) and its first Phase 2b study (DRM04-HH01), Dermira plans to initiate a Phase 3 program for DRM04 in axillary hyperhidrosis